These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29793302)

  • 1. Individualizing warfarin therapy.
    Reynolds KK; Valdes R; Hartung BR; Linder MW
    Per Med; 2007 Feb; 4(1):11-31. PubMed ID: 29793302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is personalized medicine a dream or a reality?
    Morse BL; Kim RB
    Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of warfarin.
    Kamali F; Wynne H
    Annu Rev Med; 2010; 61():63-75. PubMed ID: 19686083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of vitamin K antagonists: useful or hype?
    Lippi G; Franchini M; Favaloro EJ
    Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
    Siguret V; Pautas E; Gouin-Thibault I
    Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of target genes across the warfarin pharmacological pathway.
    Lal S; Jada SR; Xiang X; Lim WT; Lee EJ; Chowbay B
    Clin Pharmacokinet; 2006; 45(12):1189-200. PubMed ID: 17112295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
    Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
    J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of pharmacogenetics in anticoagulation therapy.
    Hill CE; Duncan A
    Clin Lab Med; 2008 Dec; 28(4):513-24. PubMed ID: 19059059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic influences on the response to warfarin.
    Kamali F
    Curr Opin Hematol; 2006 Sep; 13(5):357-61. PubMed ID: 16888441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future prospects of pharmacogenetics in oral anticoagulation therapy.
    Kamali F; Pirmohamed M
    Br J Clin Pharmacol; 2006 Jun; 61(6):746-51. PubMed ID: 16722840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
    Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
    Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
    Gage BF; Eby C; Milligan PE; Banet GA; Duncan JR; McLeod HL
    Thromb Haemost; 2004 Jan; 91(1):87-94. PubMed ID: 14691573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.